Screener
Vertex Pharmaceuticals VRTX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Vertex Pharmaceuticals’s 8-K, filed August 3, 2026. Open the filing →
- Filed
- Aug 3, 2026, 4:09 PM EDT
- Accession
- 0000875320-26-000256
FAQ
- What is Vertex Pharmaceuticals's total liabilities & equity?
- Vertex Pharmaceuticals (VRTX) reported total liabilities & equity of $27.42B in Q2 2026.
- How has Vertex Pharmaceuticals's total liabilities & equity changed year-over-year?
- Vertex Pharmaceuticals's total liabilities & equity increased by 14.1% year-over-year, from $24.04B to $27.42B.
- What is the long-term trend for Vertex Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's total liabilities & equity has grown at a 16.9% compound annual growth rate (CAGR), from $11.75B to $25.64B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Vertex Pharmaceuticals's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude